Rheumatoid arthritis patients achieved better quality of life than systemic lupus erythematosus patients at sustained remission.
In 2004 and 1999, respectively, recent-onset rheumatoid arthritis (RA) and systemic lupus erythematous (SLE) cohorts were initiated; the 36 item Medical Outcome Study Short-Form survey (SF-36) was applied beginning from enrolment. The objectives were to compare the SF-36v2 scores between patients from both cohorts who achieved sustained remission and to define the role of disease diagnosis as associated to SF-36v2 normative data in remission patients. Sustained remission was considered when RA and SLE patients achieved at least 12 months of continuous follow-up with either SLE disease activity index 2000 update =0 or Disease Activity Score (28 joints) ≤2.4, respectively. Up to December 2015, data from 172 RA patients and 211 SLE patients were reviewed. SF-36v2 scores were available for the totality of remission assessments. Logistic regression models were used to investigate factors associated with normative SF-36v2. Written informed consent was obtained from all patients. A higher proportion of patients achieved sustained remission sooner in the RA cohort than in the SLE cohort, 58% vs. 30.6% of the patients, after 30.8±23.9 vs. 59.4±37.5 months, respectively, p≤0.001. At sustained remission, RA patients scored better than SLE patients in 6 out of 8 domains of the SF-36v2 and the physical health component summary (PHCS); the opposite figure was true for the mental component. Age (ß: 1.06, 95% CI: 1.02-1.1, p=0.03) and SLE diagnosis (ß: 9.64, 95% CI: 3.61-25.75, p≤0.001) were predictors of not achieving normative PHCS. RA patients in sustained remission achieved better quality of life than SLE patients.